Epigenetics in Melanoma Development and Drug Resistance
Author:
Publisher
InTech
Link
http://www.intechopen.com/download/pdf/57287
Reference107 articles.
1. Whiteman DC, Green AC, Olsen CM. The growing burden of invasive melanoma: Projections of incidence rates and numbers of new cases in six susceptible populations through 2031. The Journal of Investigative Dermatology. 2016;136(6):1161-1171
2. Sosman JA, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. The New England Journal of Medicine. 2012;366(8):707-714
3. Long GV, et al. Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving Dabrafenib combined with Trametinib. Journal of Clinical Oncology. 2016;34(8):871-878
4. Hodi FS, et al. Improved survival with ipilimumab in patients with metastatic melanoma. The New England Journal of Medicine. 2010;363(8):711-723
5. Larkin J, et al. Combined nivolumab and lpilimumab or monotherapy in untreated melanoma. The New England Journal of Medicine. 2015;373(1):23-34
Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Toward Precision Medicine;Genomic and Epigenomic Biomarkers of Toxicology and Disease;2022-04-27
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3